AAPL345.97+2.06 (+0.60%) ▲|ABBV286.81+0.07 (+0.02%) ▲|ABT104.13-0.76 (-0.72%) ▼|ACN236.65-10.58 (-4.28%) ▼|ADBE249.57-9.05 (-3.50%) ▼|AMAT395.82+8.23 (+2.12%) ▲|AMD559.85+28.57 (+5.38%) ▲|AMGN446.95+2.32 (+0.52%) ▲|AMT183.14-5.15 (-2.73%) ▼|AMZN254.04+4.95 (+1.99%) ▲|AVGO341.92+12.75 (+3.87%) ▲|AXP313.40-1.66 (-0.53%) ▼|BA170.20-18.11 (-9.62%) ▼|BAC50.71+0.19 (+0.37%) ▲|BKNG150.71-2.44 (-1.59%) ▼|BLK1,131.37+3.71 (+0.33%) ▲|BMY61.29-0.32 (-0.52%) ▼|BNY147.72+0.54 (+0.37%) ▲|BRK-B545.02-3.54 (-0.65%) ▼|C122.68+1.64 (+1.35%) ▲|CAT713.23+21.10 (+3.05%) ▲|CL92.06-1.05 (-1.12%) ▼|CMCSA21.81-0.25 (-1.11%) ▼|COF204.16+1.81 (+0.89%) ▲|COP148.20-3.18 (-2.10%) ▼|COST992.04-13.12 (-1.31%) ▼|CRM241.95-5.66 (-2.29%) ▼|CSCO111.53+1.29 (+1.17%) ▲|CVS91.35-1.18 (-1.28%) ▼|CVX229.08-2.93 (-1.26%) ▼|DE639.64-1.61 (-0.25%) ▼|DHR232.12-0.85 (-0.36%) ▼|DIS109.86-0.54 (-0.49%) ▼|DUK124.10-0.34 (-0.27%) ▼|EMR165.60+3.90 (+2.41%) ▲|FDX307.15+6.57 (+2.19%) ▲|GD355.10-1.94 (-0.54%) ▼|GE298.08+9.65 (+3.35%) ▲|GEV887.49+32.87 (+3.85%) ▲|GILD157.94-0.75 (-0.47%) ▼|GM80.55+4.24 (+5.56%) ▲|GOOG318.30+4.11 (+1.31%) ▲|GOOGL321.90+5.10 (+1.61%) ▲|GS911.91+18.63 (+2.09%) ▲|HD318.79-0.59 (-0.18%) ▼|HON217.61-1.67 (-0.76%) ▼|IBM250.38-3.07 (-1.21%) ▼|INTC93.38+2.91 (+3.21%) ▲|INTU326.19-13.70 (-4.03%) ▼|ISRG446.61-5.02 (-1.11%) ▼|JNJ268.49+2.19 (+0.82%) ▲|JPM336.16+2.12 (+0.63%) ▲|KO91.65-1.05 (-1.13%) ▼|LIN507.11-0.45 (-0.09%) ▼|LLY1,281.29+2.15 (+0.17%) ▲|LMT623.94-11.26 (-1.77%) ▼|LOW197.99-0.23 (-0.12%) ▼|LRCX240.52+3.02 (+1.27%) ▲|MA607.95-5.55 (-0.90%) ▼|MCD249.67-1.17 (-0.46%) ▼|MDLZ62.05-0.93 (-1.47%) ▼|MDT94.36-0.43 (-0.45%) ▼|META622.57-8.00 (-1.27%) ▼|MMM171.83-0.96 (-0.56%) ▼|MO73.35-0.28 (-0.37%) ▼|MRK142.18+1.57 (+1.12%) ▲|MS187.39+3.90 (+2.13%) ▲|MSFT531.20-1.40 (-0.26%) ▼|MU931.47+27.77 (+3.07%) ▲|NEE82.19+0.15 (+0.18%) ▲|NFLX62.71-1.20 (-1.87%) ▼|NKE37.44-0.48 (-1.25%) ▼|NOW155.64-2.54 (-1.61%) ▼|NVDA217.78+1.78 (+0.82%) ▲|ORCL131.60+5.54 (+4.39%) ▲|PEP132.66-2.80 (-2.07%) ▼|PFE29.75-0.05 (-0.15%) ▼|PG158.98-0.94 (-0.59%) ▼|PLTR199.44+0.60 (+0.30%) ▲|PM203.18+1.31 (+0.65%) ▲|QCOM181.79+2.19 (+1.22%) ▲|RTX195.29-2.20 (-1.11%) ▼|SBUX102.52-0.18 (-0.17%) ▼|SCHW89.62-0.11 (-0.12%) ▼|SO92.14-0.44 (-0.47%) ▼|SPG211.92-0.77 (-0.36%) ▼|T20.98+0.13 (+0.60%) ▲|TMO698.34+13.45 (+1.96%) ▲|TMUS147.04+0.11 (+0.07%) ▲|TSLA406.03+14.41 (+3.68%) ▲|TXN307.36+9.24 (+3.10%) ▲|UBER65.90-0.24 (-0.36%) ▼|UNH409.45-1.25 (-0.30%) ▼|UNP299.26+2.29 (+0.77%) ▲|UPS105.72+5.40 (+5.38%) ▲|USB59.77+0.07 (+0.11%) ▲|V398.62-5.54 (-1.37%) ▼|VZ43.79+0.69 (+1.59%) ▲|WFC82.76+0.11 (+0.13%) ▲|WMT118.96-1.34 (-1.11%) ▼|XOM180.97-3.57 (-1.93%) ▼|AAPL345.97+2.06 (+0.60%) ▲|ABBV286.81+0.07 (+0.02%) ▲|ABT104.13-0.76 (-0.72%) ▼|ACN236.65-10.58 (-4.28%) ▼|ADBE249.57-9.05 (-3.50%) ▼|AMAT395.82+8.23 (+2.12%) ▲|AMD559.85+28.57 (+5.38%) ▲|AMGN446.95+2.32 (+0.52%) ▲|AMT183.14-5.15 (-2.73%) ▼|AMZN254.04+4.95 (+1.99%) ▲|AVGO341.92+12.75 (+3.87%) ▲|AXP313.40-1.66 (-0.53%) ▼|BA170.20-18.11 (-9.62%) ▼|BAC50.71+0.19 (+0.37%) ▲|BKNG150.71-2.44 (-1.59%) ▼|BLK1,131.37+3.71 (+0.33%) ▲|BMY61.29-0.32 (-0.52%) ▼|BNY147.72+0.54 (+0.37%) ▲|BRK-B545.02-3.54 (-0.65%) ▼|C122.68+1.64 (+1.35%) ▲|CAT713.23+21.10 (+3.05%) ▲|CL92.06-1.05 (-1.12%) ▼|CMCSA21.81-0.25 (-1.11%) ▼|COF204.16+1.81 (+0.89%) ▲|COP148.20-3.18 (-2.10%) ▼|COST992.04-13.12 (-1.31%) ▼|CRM241.95-5.66 (-2.29%) ▼|CSCO111.53+1.29 (+1.17%) ▲|CVS91.35-1.18 (-1.28%) ▼|CVX229.08-2.93 (-1.26%) ▼|DE639.64-1.61 (-0.25%) ▼|DHR232.12-0.85 (-0.36%) ▼|DIS109.86-0.54 (-0.49%) ▼|DUK124.10-0.34 (-0.27%) ▼|EMR165.60+3.90 (+2.41%) ▲|FDX307.15+6.57 (+2.19%) ▲|GD355.10-1.94 (-0.54%) ▼|GE298.08+9.65 (+3.35%) ▲|GEV887.49+32.87 (+3.85%) ▲|GILD157.94-0.75 (-0.47%) ▼|GM80.55+4.24 (+5.56%) ▲|GOOG318.30+4.11 (+1.31%) ▲|GOOGL321.90+5.10 (+1.61%) ▲|GS911.91+18.63 (+2.09%) ▲|HD318.79-0.59 (-0.18%) ▼|HON217.61-1.67 (-0.76%) ▼|IBM250.38-3.07 (-1.21%) ▼|INTC93.38+2.91 (+3.21%) ▲|INTU326.19-13.70 (-4.03%) ▼|ISRG446.61-5.02 (-1.11%) ▼|JNJ268.49+2.19 (+0.82%) ▲|JPM336.16+2.12 (+0.63%) ▲|KO91.65-1.05 (-1.13%) ▼|LIN507.11-0.45 (-0.09%) ▼|LLY1,281.29+2.15 (+0.17%) ▲|LMT623.94-11.26 (-1.77%) ▼|LOW197.99-0.23 (-0.12%) ▼|LRCX240.52+3.02 (+1.27%) ▲|MA607.95-5.55 (-0.90%) ▼|MCD249.67-1.17 (-0.46%) ▼|MDLZ62.05-0.93 (-1.47%) ▼|MDT94.36-0.43 (-0.45%) ▼|META622.57-8.00 (-1.27%) ▼|MMM171.83-0.96 (-0.56%) ▼|MO73.35-0.28 (-0.37%) ▼|MRK142.18+1.57 (+1.12%) ▲|MS187.39+3.90 (+2.13%) ▲|MSFT531.20-1.40 (-0.26%) ▼|MU931.47+27.77 (+3.07%) ▲|NEE82.19+0.15 (+0.18%) ▲|NFLX62.71-1.20 (-1.87%) ▼|NKE37.44-0.48 (-1.25%) ▼|NOW155.64-2.54 (-1.61%) ▼|NVDA217.78+1.78 (+0.82%) ▲|ORCL131.60+5.54 (+4.39%) ▲|PEP132.66-2.80 (-2.07%) ▼|PFE29.75-0.05 (-0.15%) ▼|PG158.98-0.94 (-0.59%) ▼|PLTR199.44+0.60 (+0.30%) ▲|PM203.18+1.31 (+0.65%) ▲|QCOM181.79+2.19 (+1.22%) ▲|RTX195.29-2.20 (-1.11%) ▼|SBUX102.52-0.18 (-0.17%) ▼|SCHW89.62-0.11 (-0.12%) ▼|SO92.14-0.44 (-0.47%) ▼|SPG211.92-0.77 (-0.36%) ▼|T20.98+0.13 (+0.60%) ▲|TMO698.34+13.45 (+1.96%) ▲|TMUS147.04+0.11 (+0.07%) ▲|TSLA406.03+14.41 (+3.68%) ▲|TXN307.36+9.24 (+3.10%) ▲|UBER65.90-0.24 (-0.36%) ▼|UNH409.45-1.25 (-0.30%) ▼|UNP299.26+2.29 (+0.77%) ▲|UPS105.72+5.40 (+5.38%) ▲|USB59.77+0.07 (+0.11%) ▲|V398.62-5.54 (-1.37%) ▼|VZ43.79+0.69 (+1.59%) ▲|WFC82.76+0.11 (+0.13%) ▲|WMT118.96-1.34 (-1.11%) ▼|XOM180.97-3.57 (-1.93%) ▼|
14.6 C
New York
Tuesday, October 27, 2026

Tag: Swedish Orphan Biovitrum AB

Sobi Q3 2026 report: Underpinning a strong growth momentum

STOCKHOLM, Oct. 27, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2026 Third Quarter 2026Total revenue increased...

Sobi Q3 2026 report: Underpinning a strong growth momentum

STOCKHOLM, Oct. 27, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2026 Third Quarter 2026Total revenue increased...

Sobi to present new Aspaveli®/Empaveli® data at ASN Kidney Week 2026

STOCKHOLM, Oct. 19, 2026 /PRNewswire/ -- Sobi® today announced that seven abstracts on Aspaveli/Empaveli (pegcetacoplan) have been accepted for presentation at the American Society...

Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)

Positive CHMP opinion based on Phase 3 CORE and CORE2 results, demonstrating a statistically significant placebo-adjusted mean reduction of up to 72% in triglyceride...

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum

STOCKHOLM, July 16, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025 Second Quarter 2025 Total revenue increased 13...

Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum

STOCKHOLM, July 16, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025 Second Quarter 2025 Total revenue increased 13...

The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under incentive programmes

STOCKHOLM, July 15, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025, resolved – for the...

The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under incentive programmes

STOCKHOLM, July 15, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025, resolved – for the...

Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases

STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSwedish Orphan Biovitrum AB